Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of PRO-229 vs Lagricel in Healthy Subjects
NCT06370585Phase 1Completed
- Sponsor
- Laboratorios Sophia
- Start
- May 2024
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of PRO-229 in dry eye disease (DED) (2 arms), sponsored by Laboratorios Sophia. Primary endpoint: Incidence Unexpected Related Adverse Reactions at Day 12. Started May 2024; status: completed.
02
Drugs
PRO-229
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT06370585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06370585.